tetano
Editor, Senior Moderator
Front Immunol
. 2022 Aug 15;13:943563.
doi: 10.3389/fimmu.2022.943563. eCollection 2022.
Clinical and immunological features associated to the development of a sustained immune humoral response in COVID-19 patients: Results from a cohort study
Jiram Torres-Ruiz[SUP] 1 [/SUP], Julieta Lomelín-Gascón[SUP] 2 [/SUP], Ana Sofía Vargas-Castro[SUP] 1 [/SUP], Jaquelin Lira-Luna[SUP] 1 3 [/SUP], Alfredo Pérez-Fragoso[SUP] 1 4 [/SUP], Roberto Tapia-Conyer[SUP] 2 5 [/SUP], Miroslava Nuñez-Aguirre[SUP] 1 4 [/SUP], Beatriz Alcalá-Carmona[SUP] 1 4 [/SUP], Abdiel Absalón-Aguilar[SUP] 1 6 [/SUP], José Luis Maravillas-Montero[SUP] 7 [/SUP], Nancy Raquel Mejía-Domínguez[SUP] 7 [/SUP], Carlos Núñez-Álvarez[SUP] 1 [/SUP], Marina Rull-Gabayet[SUP] 1 [/SUP], Luis Llorente[SUP] 1 [/SUP], Sandra Romero-Ramírez[SUP] 7 [/SUP], Victor Andrés Sosa-Hernández[SUP] 7 [/SUP], Rodrigo Cervantes-Díaz[SUP] 7 [/SUP], Guillermo Juárez-Vega[SUP] 7 [/SUP], David Eduardo Meza-Sánchez[SUP] 7 [/SUP], Luis Alberto Martínez-Juárez[SUP] 2 8 [/SUP], Linda Morales-Juárez[SUP] 2 9 [/SUP], Lizeth Naomi López-López[SUP] 2 [/SUP], José Adrián Negrete-Trujillo[SUP] 2 [/SUP], Jorge Abelardo Falcón-Lezama[SUP] 2 10 [/SUP], Rafael Ricardo Valdez-Vázquez[SUP] 9 [/SUP], Héctor Gallardo-Rincón[SUP] 11 [/SUP], Diana Gómez-Martín[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Until now, most of the research addressing long-term humoral responses in coronavirus disease 2019 (COVID-19) had only evaluated the serum titers of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgGs, without the assessment of the baseline antiviral clinical and immune profile, which is the aim of this study and may be the key factor leading to a broad and sustained antibody response.
Methods: We included 103 patients with COVID-19. When the patients sought medical attention (baseline), a blood sample was drawn to perform immunophenotype of lymphocytes by flow cytometry. The patients were assessed 15 days after baseline and then every month until the third month, followed by a last visit 6 months after recruitment. We evaluated the anti-SARS-COV-2 IgG at all time points, and the serum levels of cytokines, chemokines, anti-cellular (AC) antibodies and neutrophil extracellular traps were also assessed during the follow-up. The primary outcome of the study was the presence of a sustained immune humoral response, defined as an anti-SARS-CoV-2 IgG titer >4.99 arbitrary units/mL in at least two consecutive measures. We used generalized lineal models to assess the features associated with this outcome and to assess the effect of the changes in the cytokines and chemokines throughout time on the development of a sustained humoral immune response.
Results: At baseline the features associated to a sustained immune humoral response were the diagnosis of critical disease, absolute number of lymphocytes, serum IP-10, IL-4, IL-2, regulatory T cells, CD8[SUP]+[/SUP] T cells, and positive AC antibodies. Critical illness and the positivity of AC antibodies were associated with a sustained humoral immune response after 3 months, whilst critical illness and serum IL-13 were the explanatory variables after 6 months.
Conclusion: A sustained immune humoral response is strongly related to critical COVID-19, which is characterized by the presence of AC antibodies, quantitative abnormalities in the T cell compartment, and the serum cytokines and chemokines during acute infection and throughout time.
Keywords: COVID-19; SARS-CoV-2; anti-cellular antibodies; humoral response; lymphopenia.
. 2022 Aug 15;13:943563.
doi: 10.3389/fimmu.2022.943563. eCollection 2022.
Clinical and immunological features associated to the development of a sustained immune humoral response in COVID-19 patients: Results from a cohort study
Jiram Torres-Ruiz[SUP] 1 [/SUP], Julieta Lomelín-Gascón[SUP] 2 [/SUP], Ana Sofía Vargas-Castro[SUP] 1 [/SUP], Jaquelin Lira-Luna[SUP] 1 3 [/SUP], Alfredo Pérez-Fragoso[SUP] 1 4 [/SUP], Roberto Tapia-Conyer[SUP] 2 5 [/SUP], Miroslava Nuñez-Aguirre[SUP] 1 4 [/SUP], Beatriz Alcalá-Carmona[SUP] 1 4 [/SUP], Abdiel Absalón-Aguilar[SUP] 1 6 [/SUP], José Luis Maravillas-Montero[SUP] 7 [/SUP], Nancy Raquel Mejía-Domínguez[SUP] 7 [/SUP], Carlos Núñez-Álvarez[SUP] 1 [/SUP], Marina Rull-Gabayet[SUP] 1 [/SUP], Luis Llorente[SUP] 1 [/SUP], Sandra Romero-Ramírez[SUP] 7 [/SUP], Victor Andrés Sosa-Hernández[SUP] 7 [/SUP], Rodrigo Cervantes-Díaz[SUP] 7 [/SUP], Guillermo Juárez-Vega[SUP] 7 [/SUP], David Eduardo Meza-Sánchez[SUP] 7 [/SUP], Luis Alberto Martínez-Juárez[SUP] 2 8 [/SUP], Linda Morales-Juárez[SUP] 2 9 [/SUP], Lizeth Naomi López-López[SUP] 2 [/SUP], José Adrián Negrete-Trujillo[SUP] 2 [/SUP], Jorge Abelardo Falcón-Lezama[SUP] 2 10 [/SUP], Rafael Ricardo Valdez-Vázquez[SUP] 9 [/SUP], Héctor Gallardo-Rincón[SUP] 11 [/SUP], Diana Gómez-Martín[SUP] 1 [/SUP]
Affiliations
- PMID: 36045688
- PMCID: PMC9421299
- DOI: 10.3389/fimmu.2022.943563
Abstract
Background: Until now, most of the research addressing long-term humoral responses in coronavirus disease 2019 (COVID-19) had only evaluated the serum titers of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgGs, without the assessment of the baseline antiviral clinical and immune profile, which is the aim of this study and may be the key factor leading to a broad and sustained antibody response.
Methods: We included 103 patients with COVID-19. When the patients sought medical attention (baseline), a blood sample was drawn to perform immunophenotype of lymphocytes by flow cytometry. The patients were assessed 15 days after baseline and then every month until the third month, followed by a last visit 6 months after recruitment. We evaluated the anti-SARS-COV-2 IgG at all time points, and the serum levels of cytokines, chemokines, anti-cellular (AC) antibodies and neutrophil extracellular traps were also assessed during the follow-up. The primary outcome of the study was the presence of a sustained immune humoral response, defined as an anti-SARS-CoV-2 IgG titer >4.99 arbitrary units/mL in at least two consecutive measures. We used generalized lineal models to assess the features associated with this outcome and to assess the effect of the changes in the cytokines and chemokines throughout time on the development of a sustained humoral immune response.
Results: At baseline the features associated to a sustained immune humoral response were the diagnosis of critical disease, absolute number of lymphocytes, serum IP-10, IL-4, IL-2, regulatory T cells, CD8[SUP]+[/SUP] T cells, and positive AC antibodies. Critical illness and the positivity of AC antibodies were associated with a sustained humoral immune response after 3 months, whilst critical illness and serum IL-13 were the explanatory variables after 6 months.
Conclusion: A sustained immune humoral response is strongly related to critical COVID-19, which is characterized by the presence of AC antibodies, quantitative abnormalities in the T cell compartment, and the serum cytokines and chemokines during acute infection and throughout time.
Keywords: COVID-19; SARS-CoV-2; anti-cellular antibodies; humoral response; lymphopenia.